Abstract Number: 2569 • ACR Convergence 2023
Efficacy and Safety of Therapeutic Interventions for the Treatment of Still’s Disease: A Systematic Review and Meta-analysis Informing the EULAR/PReS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease
Background/Purpose: To investigate the efficacy and safety of therapies currently in use and under evaluation for systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-Onset Still's disease…Abstract Number: 0228 • ACR Convergence 2023
A Comprehensive Retrospective Analysis of Polymyalgia Rheumatica in Long COVID Patients at an Academic Medical Center in the Midwest
Background/Purpose: Polymyalgia Rheumatica (PMR) is an inflammatory disorder that predominantly affects older adults. Incidence peaks at 70-80 years old [1] and is more common in…Abstract Number: 0585 • ACR Convergence 2023
The Impact of Impaired Vagus Nerve Activity and Transcutaneous Vagus Nerve Stimulation (tVNS) on Arterial Stiffness in Systemic Lupus Erythematosus (SLE)
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease with an increased risk of atherosclerosis. The development of atherosclerosis in SLE cannot be…Abstract Number: 0940 • ACR Convergence 2023
A Novel Therapeutic Opportunity in Systemic Sclerosis: The Fibrolytic Activities of a Specialized Macrophage Secretome
Background/Purpose: Systemic sclerosis (SSc) a complex and rare immune-mediated connective tissue disorder characterized by microvascular damage, inflammatory cell infiltration, and excessive deposition of extracellular matrix…Abstract Number: 1247 • ACR Convergence 2023
Pharmacokinetic, Pharmacodynamic, and Safety Profile of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: Analysis of Data from a Multicenter, Open-Label Trial
Background/Purpose: Belimumab (BEL) is an approved treatment for SLE, in addition to standard therapy. Intravenous (IV) BEL is approved in patients (pts) ≥5 years of…Abstract Number: 1717 • ACR Convergence 2023
Endothelial Cell Sphingosine 1-Phophate Receptor 1 Restrains VE-cadherin Cleavage and Attenuates Experimental Inflammatory Arthritis
Background/Purpose: In rheumatoid arthritis, inflammatory mediators extravasate from blood into joints via gaps between endothelial cells (EC), but the contribution of ECs to inflammatory arthritis…Abstract Number: 1778 • ACR Convergence 2023
Role of GITR/GITRL Interaction in Modulating T Helper 9, T Helper 17 and T Regulatory Response in Psoriatic Arthritis
Background/Purpose: The inflammatory process characterizing Psoriatic Arthritis (PsA) is mainly driven by interleukin (IL)-23/IL-17 axis and IL-9 overexpression, in presence of T helper (Th)17 and…Abstract Number: 2221 • ACR Convergence 2023
Clinical and Molecular Patterns Associated with Persistence of Inflammation in Spondyloarthritis Patients: Unveiling Potential Biomarkers
Background/Purpose: Chronic inflammation is closely associated with an increased risk of cardiovascular diseases (CVD) through the activation of the immune system and the release of…Abstract Number: 2570 • ACR Convergence 2023
Thrombosis in Patients with VEXAS Syndrome: A Retrospective Cohort Study
Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, due to somatic mutations in the UBA1 gene, is an autoinflammatory disorder associated with an increased…Abstract Number: 0278 • ACR Convergence 2023
NOD2 Genotyping Landscape in Yao Syndrome
Background/Purpose: Yao syndrome (YAOS, OMIM 617321) is formerly designated NOD2-associated autoinflammatory disease. A spectrum of NOD2 mutations have been associated with this disease. This study…Abstract Number: 0756 • ACR Convergence 2023
Validation of Quantitative Effusion-synovitis Volume Measured by Deep-learning: Data from the Osteoarthritis Initiative
Background/Purpose: Knee effusion-synovitis (ES) is an attractive target for therapeutic interventions in arthritis, since it is associated with stiffness, pain, and disease progression to arthroplasty.…Abstract Number: 0947 • ACR Convergence 2023
Fcγ Receptors Define Pro-Phagocytic Macrophages and Trigger Pro-Inflammatory Responses in Patients with Systemic Sclerosis
Background/Purpose: Fcy receptors (FcγR) are opsonic phagocytic receptors, requiring tight regulations to prevent uncontrolled activation of pro-inflammatory phagocytosis. SSc macrophages display an alternatively-activated profibrotic phenotype.…Abstract Number: 1265 • ACR Convergence 2023
Changes in the Endocannabinoid Tone in Rheumatoid Arthritis and Osteoarthritis – Discovery of a Novel Target for the Treatment of Pain and Inflammation?
Background/Purpose: Inflammation is a complicated physiological process that results in a variety of disorders. Several inflammatory mediators are produced during this process, which is responsible…Abstract Number: 1725 • ACR Convergence 2023
Distinct Perivascular and Intravascular Lymphatic Mast Cells and Their Role in Lymphatic Clearance, Joint Inflammation, and Bone Erosion in the TNF-Transgenic Murine Arthritis Model
Background/Purpose: Inflammatory-erosive arthritis is exacerbated by lymphatic dysfunction (1), and mast cells (MCs) regulate lymphatic vessel contractions via release of inflammatory and vasoactive mediators (2).…Abstract Number: 1779 • ACR Convergence 2023
A Novel Inhibitory Pathway of Synovial Inflammation Exerted by Glucocorticoids and TNF Inhibitors Through LAG-3 Up-Regulation
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated condition that results in systemic musculoskeletal (MSK) inflammation, including peripheral synovitis, enthesitis and axial involvement. Glucocorticoids (GCs)…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 58
- Next Page »